Nuformix (LON:NFX) Posts Quarterly Earnings Results

Nuformix (LON:NFX) posted its quarterly earnings results on Thursday. The company reported GBX (0.02) earnings per share (EPS) for the quarter, Digital Look Earnings reports.

Nuformix Stock Performance

Nuformix stock opened at GBX 0.17 on Thursday. The firm’s 50-day moving average is GBX 0.18 and its 200-day moving average is GBX 0.23. Nuformix has a 1 year low of GBX 0.01 and a 1 year high of GBX 0.56. The company has a market cap of £4.44 million, a P/E ratio of -4.33 and a beta of 1.55.

Nuformix Company Profile

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.